1604813-29-7

Basic information

• Product Name: tert-butyl (3-(4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate
• Synonyms: tert-butyl (3-(4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate
• CAS NO: 1604813-29-7
• Molecular Weight: 775.066
• Mol File: 1604813-29-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl (3-(4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3-(4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate(1604813-29-7)
• EPA Substance Registry System: tert-butyl (3-(4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate(1604813-29-7)

Safety Data

• Hazardous Substances Data: 1604813-29-7(Hazardous Substances Data)

Upstream product

• 1604813-28-6 4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzoic acid 
• 292606-35-0 N-tert-butyloxycarbonyl-2,2-dimethyl-1,3-propanediamine 
• 1604813-26-4 tert-butyl 4-((4-((3-chloro-4-hydroxybenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzoate 
• 1604813-27-5 tert-butyl 4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzoate 
• 185677-00-3 2,4-dichloro-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine 
• 1287220-82-9 tert-butyl 4-{[4-chloro-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino}benzoate 
• 859517-85-4 4-(aminomethyl)-2-chlorophenol hydrobromide 

Downstream Products

• 1622008-98-3 C₃₄H₃₄ClF₃N₈O₇ 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infect